Rethinking cancer clinical trial conduct induced by covid-19: An academic center, industry, government, and regulatory agency perspective

27Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

The COVID-19 pandemic brought about major changes in cancer clinical trials. In its aftermath, the community has an opportunity to incorporate some of these changes as part of the future of trial conduct to make it more patient centered.

Cite

CITATION STYLE

APA

Flaherty, K. T., Doroshow, J. H., Galbraith, S., Ribas, A., Kluetz, P. G., Pazdur, R., & Theoret, M. R. (2021). Rethinking cancer clinical trial conduct induced by covid-19: An academic center, industry, government, and regulatory agency perspective. Cancer Discovery, 11(8), 1881–1885. https://doi.org/10.1158/2159-8290.CD-21-0850

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free